

SLT Photoregeneration

fact sheet

- Glaucoma is today the leading cause of blindness in North America and Europe, and the second leading cause worldwide after cataract.
- SLT is a proven treatment. Approved by the US Food and Drug Administration (FDA) in 2001, thousands of patients around the world have benefited from the procedure. Long-term studies have followed patients over as much as six years without any negative findings.
- SLT can be used as a primary stand-alone therapy or in conjunction with drug therapy.
- SLT is repeatable. The treatment can be repeated, if necessary, depending on the individual patient's response, as well as conducted at regular intervals to keep intraocular pressure stable and low.
- There are no major risks or complications associated with SLT. The worst that can happen is that the patient's eye does not respond. The average response rate is over 70%.
- SLT is completely non-invasive and does not cause any harmful damage or scarring to the surrounding tissue.
- SLT is quick. The laser procedure itself takes approximately 5 minutes, the total average treatment time is 30 minutes.
- In the majority of patients, there is often an immediate decrease in intraocular pressure following SLT treatment. However, in some patients the photoregenerative process may take from weeks to a few months before impacting eye pressure.
- SLT is an effective treatment method for patients with primary open angle glaucoma, normal tension glaucoma, pseudoexfoliation glaucoma or pigmentary glaucoma. Studies are currently undergoing for the treatment of angle closure glaucoma.

